Early Cancer Detection Matters
Everyone knows someone with Cancer. Unfortunately, almost 50% of people are diagnosed too late when outcomes are the poorest. (1)
Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier.
Find out if you’re eligible for the Aristotle test.
It's Time to Remove the Obstacles to
Early Cancer Detection
A late stage cancer diagnosis can be attributed to many factors.
- Postponing cancer screening
- Cancer doesn’t show symptoms until it’s progressed
- A lack of convenient screening options
Don’t put off your cancer screening. Contact us today to learn if the Aristotle test is right for you.
|Cancer Type||5 Year Survival Rate when Found Early (1) (Localized)||5 Year Survival Rate when Found Late (1) (Distant)|
Why Early Is Better
Although cancer can be a scary diagnosis, several types of cancer are fully treatable. Outcomes are especially improved when cancer is found in the early stages.
For instance, when Colorectal Cancer is found early it has a five year survival rate of 91%, but when found late, it has a 14% survival rate.(1) When Breast Cancer is found early the 5-year survival rate is 99%, but when found late it has a 28% survival rate.(1)
Contact us to find out if the Aristotle blood test is right for you.
The Science Behind the Aristotle Test
Aristotle® uses mRNA technology to detect multiple cancer signatures from a single sample of blood. It’s similar to looking for a fingerprint that cancer leaves behind.
Aristotle® is built on StageZero Life Sciences’ proprietary technology platform, The Sentinel Principle®, which has demonstrated that circulating blood reflects, in a detectable way, what is occurring throughout the body. (3) The Sentinel Principle® has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
What Cancer Signatures Can Aristotle Detect?
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Liver Cancer
- Colorectal Cancer
- Stomach Cancer
- Bladder Cancer
- Prostate Cancer
How it Works
Complete your online intake form to determine your eligibility for testing.
After you make your secure online payment for your test, we’ll schedule testing at a lab near your or arrange for a mobile phlebotomist to come to your home.
When we receive your test results, we’ll reach out to schedule a time to review them with a telehealth physician.
Additional Testing for Early Cancer Detection
In addition to the AVRT panel, we offer advanced blood tests for early cancer detection*. These tests are offered by StageZero Life Sciences, a CLIA Certified, CAP Accredited High Complexity Laboratory in Richmond, VA. Be sure to ask an AVRT representative about any of the tests below. Pricing and availability vary.
* These tests are priced separately and not included in the cost of the AVRT Panel & Physician Consult.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
- American Institute of Cancer Research (AICR.org) accessed October 28, 2021
- Dempsey A, Chao S, Stamatiou D, et al., Aristotle: A single blood test for pan-cancer screening. Journal of Clinical Oncology. 2020; 38:15_suppl, e15037-e15037
- Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system-wide biology: a potential diagnostic tool. J Lab Clin Med. 2006 Mar;147(3):126-32.
- Melander O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer. Cancer Epidemiology and Prevention Biomarkers 23.8 (2014): 1672-1676.
- Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655
- Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169